Hands reviewing anonymous supplement label panels

FDA Supplement Disclaimer: Why the 30 Days' Notice Controls Claims

Sep 29, 2026James Brown

What the DSHEA/FDA disclaimer is and when it’s required

The disclaimer traces back to the Dietary Supplement Health and Education Act of 1994 and its implementing rule, 21 CFR 101.93, which ties the requirement to section 403®(6) of the Food, Drug, and Cosmetic Act. Any supplement label or advertisement that makes a claim under that section has to carry the disclaimer, in the exact wording the regulation specifies.

Three categories of claims trigger the requirement. A structure/function claim describes how an ingredient affects the body’s normal structure or function, such as “supports healthy joints.” A general well-being claim addresses overall vitality or energy without pointing to a specific body system. A nutrient-deficiency claim describes a product’s role in preventing a deficiency disease, such as vitamin C and scurvy, and must also state how common that deficiency is in the United States.

None of these three claim types requires FDA pre-approval, but they all require the manufacturer to notify FDA within 30 days of first marketing the product with that claim, a requirement confirmed by NIH’s Office of Dietary Supplements. That notification is a paperwork filing, not a review process, and FDA does not approve or reject it before the product reaches shelves.

This is where supplement labeling diverges sharply from conventional food labeling. A food label can state a nutrient’s role in a health outcome under an authorized health claim only after FDA has reviewed the supporting science and issued a specific regulation permitting the wording. A supplement label making a structure/function claim skips that pre-market review entirely, provided:

The claim does not state or imply that the product diagnoses, treats, cures, or prevents a disease.
The manufacturer has substantiation on file before the claim is made, not after.
The required disclaimer appears on the label in the specified format.
The 30-day notification has been filed with FDA’s Center for Food Safety and Applied Nutrition.

The tradeoff is speed for scrutiny: supplements move to market faster than drugs, but the burden of proof shifts entirely to the manufacturer, and the government reserves the right to challenge that proof after the fact.

Exact wording, placement, and formatting rules for labels

FDA’s Dietary Supplement Labeling Guide spells out the disclaimer word for word. The singular version, used when a label carries one qualifying statement, reads exactly: “This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.”

When a label carries more than one structure/function statement, a plural version applies instead, referring to “these statements” rather than “this statement.” The regulation’s text requires the disclaimer to appear on every panel or page where a qualifying claim is printed, not just once somewhere on the packaging.

Placement follows one of two paths. The disclaimer can sit immediately adjacent to the claim it modifies, with no intervening text or graphics. Alternatively, it can appear elsewhere on the label inside a box, provided the claim itself carries a reference symbol (commonly an asterisk) linking it to the boxed disclaimer.

Minimum type size for the disclaimer is 1/16 inch, and the text must be set in boldface, according to 21 CFR 101.93. A disclaimer printed at a smaller size, in a light font weight, or tucked into fine print at the bottom of a label fails the formatting requirement even if the wording is correct.

Acceptable: a claim on the front panel with an asterisk, linked to a boxed, bolded disclaimer on the side panel in 1/16-inch type.
Unacceptable: the same claim with the disclaimer printed only on an insert card that ships inside the bottle but never appears on the label itself.

Why the disclaimer doesn’t turn a claim into a drug approval

The legal line that matters most is the one between a structure/function claim and a disease claim. A structure/function claim describes a normal physiological role, such as supporting energy metabolism. A disease claim states or implies that a product diagnoses, treats, cures, mitigates, or prevents a specific disease, such as erectile dysfunction, diabetes, or depression.

FDA does not read labels claim by claim in isolation. The agency and courts look at the totality of marketing: label text, packaging graphics, the product name itself, website copy, and social media posts. A structure/function claim on the bottle paired with disease-implying language on the brand’s website can still push the whole product into “unapproved new drug” territory, disclaimer or not.

Wording that tends to draw scrutiny includes:

References to a named condition (such as a specific diagnosis) rather than a general body function.
Comparative language suggesting the product works like or replaces a prescription drug.
Testimonials describing recovery from a diagnosed illness.
Claims of “curing,” “treating,” or “reversing” a condition rather than “supporting” a function.

The disclaimer never authorizes crossing that line. It exists to clarify that the specific statement it accompanies is a structure/function claim, not to insulate a product from scrutiny if the rest of its marketing reads like a drug pitch. A supplement can carry a technically compliant disclaimer and still be misbranded if its overall presentation implies disease treatment.

Enforcement risks: warning letters and real cases

FDA’s primary enforcement tools are warning letters, product seizures, and injunctions, all grounded in the misbranding and unapproved new drug provisions of the FD&C Act. A warning letter is typically the first step: it identifies specific violative claims and gives the company a window to correct them before more serious action follows.

One instructive example is the OptiHealth Products warning letter, where FDA treated a supplement as an unapproved new drug because its marketing claims crossed from structure/function language into disease treatment territory. Once FDA makes that determination, the disclaimer on the label does not change the outcome.

Common violations found in warning letters include claims that a product treats or prevents a named disease, therapeutic language borrowed from clinical contexts, and health claims made during public health events that imply protection against a specific illness. FTC, which shares jurisdiction over advertising, holds companies to a standard of competent and reliable scientific evidence for any health claim made in ads, a standard illustrated in FDA and FTC’s coordinated action against Chromadex.

Practical red flags for anyone writing supplement marketing:

Naming a specific disease or diagnosis anywhere in claim language.
Using words like “cure,” “treat,” or “prevent” outside the disclaimer itself.
Letting website or social copy make claims the label carefully avoids.
Relying on customer testimonials that describe disease outcomes rather than general wellness.

A compliance checklist for supplement manufacturers

Manufacturers carry the substantiation burden from day one, and FDA’s inspectional guidance, CP 7321.008, confirms that label review during inspections specifically checks disclaimer placement and notification records. A practical sequence looks like this:

Build a substantiation file before finalizing any structure/function claim, including studies, ingredient research, and rationale, kept on hand and ready for inspection.
File the 30-day notification with FDA’s Center for Food Safety and Applied Nutrition before or promptly after the product with the new claim first ships.
Confirm every label element: correct disclaimer text and placement, a complete Supplement Facts panel, a domestic address or phone number for adverse event reporting, and a full ingredient list.
Follow current Good Manufacturing Practice requirements for the facility, and keep supplier certificates of analysis and reserve samples on file.
Maintain a single master label file that shows each claim next to its disclaimer, alongside the notification cover letter and substantiation documents, so an inspector can review everything in one place.

Pro Tip: Inspectors under CP 7321.008 frequently cite missing 30-day notifications and thin substantiation files as the most common findings, so keep both indexed and dated rather than scattered across email threads.

Manufacturers who treat this as an ongoing recordkeeping habit, not a one-time label approval step, tend to avoid the gaps that trigger warning letters in the first place.

What FDA’s December 2025 letter signals for label rules

On December 11, 2025, FDA issued a letter to industry about the DSHEA disclaimer, acknowledging industry concerns that the current disclaimer language adds clutter to already crowded supplement labels. The letter raised the possibility of modernizing the requirement.

The key point for manufacturers right now is that the letter is a signal of intent, not a rule change. FDA explicitly noted that the current regulatory text in 21 CFR 101.93 remains binding, and any actual revision would require formal rulemaking or new guidance before labels could legally change.

Practically, that means:

Keep using the exact current disclaimer text and formatting until a final rule or guidance document says otherwise.
Do not preemptively shorten or reformat the disclaimer based on the letter alone.
Watch FDA’s dietary supplement guidance page and constituent updates for any proposed rule or draft guidance that follows.
Document your labels as they stand now, so you have a clear before-and-after record if requirements change.

How Organic Fuel builds compliance into every label

Organic Fuel’s herbal supplements are formulated with proprietary organic ingredients, lab-tested in the United States, manufactured at FDA-registered, GMP-certified facilities. Every product carries the disclaimer language current regulation requires, placed and sized to meet the labeling guide’s formatting rules.

Substantiation records, supplier documentation, and certification details are kept on file the same way the checklist above describes, and readers can review safety and testing practices directly.

The disclaimer is a floor, not a shield

The most common misreading of this disclaimer treats it as legal cover, a kind of magic phrase that lets any wellness claim slide. It is the opposite: it is the minimum admission that a claim has not been vetted by any government body, paired with a strict boundary on what that claim can say.

Conventional compliance advice focuses almost entirely on getting the disclaimer’s text and font size right, and that part is easy to check. What gets missed is the marketing environment around the label: the website copy, the influencer post, the customer testimonial describing a diagnosed condition. FDA and FTC read all of it together, and a technically perfect label sitting next to disease-implying ad copy will not survive scrutiny.

If you manufacture or market supplements, prioritize the substantiation file and the 30-day notification before worrying about label typography. Those two things are what an inspector actually asks for, and they are what separates a defensible structure/function claim from an unapproved drug claim wearing a disclaimer as camouflage.

— Organic

See Organic Fuel’s labeling and certifications firsthand

Organic Fuel’s product pages show exactly how these rules apply in practice. Alpha Cactus supports stamina and drive, the Bad Boy Bundle pairs complementary formulas for men, and Ageless For Men targets natural vitality support, each with disclaimer language and Supplement Facts you can review before buying.

Every listing links to lab-testing and certification details, so you can check GMP status and sourcing before you order. Browse the full product collection or reach out through the site for labeling or bulk order questions.

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.

Sources

FAQ

What is the FDA supplement disclaimer?

It is the required label statement clarifying that FDA has not evaluated a structure/function or well-being claim and that the product is not meant to diagnose, treat, cure, or prevent disease. The exact wording and formatting come from 21 CFR 101.93.

What does an FDA warning letter mean for a supplement?

A warning letter means FDA has identified specific label or marketing claims it considers violations, often because the claims imply disease treatment rather than a structure/function benefit. The OptiHealth Products letter shows how disease-implying claims can lead FDA to treat a supplement as an unapproved drug.

What is the FDA’s regulation on dietary supplements?

Dietary supplements are regulated under DSHEA and 21 CFR 101.93, which governs the claims a label can make and the disclaimer those claims require. Supplements are not reviewed or approved by FDA before they reach the market, though manufacturers must notify the agency within 30 days of marketing a new structure/function claim.

Does a supplement need FDA approval before it’s sold?

No, dietary supplements do not require FDA approval before marketing, unlike prescription or over-the-counter drugs. Manufacturers are responsible for ensuring their products are safe and their claims truthful, a responsibility NIH’s Office of Dietary Supplements confirms rests entirely with the company, not the government, prior to sale.

FDA Supplement Disclaimer: Why the 30 Days' Notice Controls Claims

More articles

Comments (0)

Leave a comment

Supported payment methods

Organic Fuel

Quick links

Contact information

Social Media

Table of Contents